Amgen Presents New Data From Phase 3 XGEVA ® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017

Analysis Demonstrated XGEVA had a Significantly Lower Rate of Renal Adverse Events Compared to Zoledronic Acid Data Selected for Best of ASCO® Educational Program THOUSAND OAKS, Calif., June 4, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the XGEVA® (denosumab) Phase 3 '482 study, the largest international multiple myeloma trial ever conducted. The study met its primary endpoint, demonstrating XGEVA is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.14; p=0.01). The analysis demonstrated that patients on XGEVA had a significantly lower rate of rena...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news